https://www.thebodypro.com/author/josep-m-llibre
Josep M. Llibre, M.D., Ph.D.

Josep M. Llibre, M.D., Ph.D.

Latest by Josep M. Llibre, M.D., Ph.D.

The Future of 2-Drug Regimens for People With HIV Img
Features

The Future of 2-Drug Regimens for People With HIV

Reducing the number of drugs in a treatment regimen lowers long-term drug exposure and potential drug toxicity or drug interactions. What can we expect in the future for two-drug regimens?

By Josep M. Llibre, M.D., Ph.D.
Tenofovir Alafenamide (TAF) Shows Better Safety Profile Than Old Tenofovir Img
Conference Coverage

Tenofovir Alafenamide (TAF) Shows Better Safety Profile Than Old Tenofovir

We may have finally seen the arrival of tenofovir alafenamide (TAF) at CROI 2015. The new formulation of tenofovir has demonstrated all that can be demonstrated at 48 weeks, in the phase-3 randomized, double-blind, double-dummy clinical trials GS104 ...

By Josep M. Llibre, M.D., Ph.D. and Benjamin Young, M.D., Ph.D.
Pre-Exposure Prophylaxis (PrEP) Works: Implementing Science Into HIV Prevention Img
Conference Coverage

Pre-Exposure Prophylaxis (PrEP) Works: Implementing Science Into HIV Prevention

Results from three big HIV prevention trials were presented in one of the key sessions at CROI 2015.

The French-Canadian IPERGAY study evaluated "on-demand" PrEP, which consisted of two pills of tenofovir/emtricitabine (Truvada), two to 24 hours pri...

By Josep M. Llibre, M.D., Ph.D. and Benjamin Young, M.D., Ph.D.
A Tenofovir-Sparing Regimen Could Be a Safer Alternative for Starting Treatment Img
Conference Coverage

A Tenofovir-Sparing Regimen Could Be a Safer Alternative for Starting Treatment

The ACTG A5303 study at CROI 2015 was a double-blind, randomized trial that compared maraviroc (Selzentry, Celsentri), at 150 mg once daily, to tenofovir (TDF, Viread) in 259 treatment-naive patients, both arms with ritonavir (Norvir)-boosted darunav...

By Josep M. Llibre, M.D., Ph.D. and Benjamin Young, M.D., Ph.D.
Curing Hepatitis C Virus in HIV-Coinfected Patients: Mission Accomplished Img
Conference Coverage

Curing Hepatitis C Virus in HIV-Coinfected Patients: Mission Accomplished

"Mission Accomplished," the title given by CROI 2015 organizers for the session on hepatitis C (HCV) treatment, was premonitional. Two big phase-3 studies in HIV/HCV coinfected individuals were presented.

In the ION-4 study, 335 patients received tw...

By Josep M. Llibre, M.D., Ph.D. and Benjamin Young, M.D., Ph.D.
Gene Therapy Overcomes Vaccines in HIV Prevention Img
Conference Coverage

Gene Therapy Overcomes Vaccines in HIV Prevention

For the HIV cure and eradication session at CROI 2015, once again, the organizers were funny in choosing the title, "Leaky Latency." In general, all reports were bad news for HIV cure. The more we learn, the higher the distance seems to HIV eradicati...

By Josep M. Llibre, M.D., Ph.D. and Benjamin Young, M.D., Ph.D.
Promo Image
Conference Coverage

Initial HIV Treatment With a 2-Drug, Nuke-Sparing Regimen Falls Short

For many years, we've wondered about the long-term safety of nucleoside/tide reverse transcriptase inhibitors (NRTIs). Our sometimes-lethal experiences with dideoxynucleosides cemented this sentiment, one that lingers today, even with far better nuke...

By Josep M. Llibre, M.D., Ph.D. and Benjamin Young, M.D., Ph.D.
Promo Image
Conference Coverage

Raltegravir Superior to Boosted Protease Inhibitors as First-Line Treatment

U.S. treatment guidelines equally recommend first-line treatment regimens that include either a non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz (Sustiva, Stocrin); one of two ritonavir (Norvir)-boosted protease inhibitors (PIs), ata...

By Josep M. Llibre, M.D., Ph.D. and Benjamin Young, M.D., Ph.D.
Promo Image
Conference Coverage

Update on GSK744 and Monthly HIV Treatment or PrEP

For months, we've been excited about emerging data regarding GSK744 (also known as "744"), an investigational integrase inhibitor, close cousin of dolutegravir (Tivicay, DTG), with the potential for once-monthly injection dosing and promise in pre-ex...

By Josep M. Llibre, M.D., Ph.D. and Benjamin Young, M.D., Ph.D.
Promo Image
Hepatitis C

The Fast-Paced Evolution of Hepatitis C Treatment and Cures

Nothing else in the history of biomedical sciences has evolved faster than the treatment of hepatitis C virus (HCV) infection. Only recently did the first direct antiviral agents (boceprevir [Victrelis] and telaprevir [Incivek]) receive FDA (U.S....

By Josep M. Llibre, M.D., Ph.D. and Benjamin Young, M.D., Ph.D.